Literature DB >> 3136940

Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

S Kerpel-Fronius1, J Verwey, M Stuurman, B Kanyár, P Lelieveld, H M Pinedo.   

Abstract

The pharmacokinetics of mitomycin (MMC) was studied in Wistar rats. Up to five half-lives, the plasma concentration-time curve was biphasic. The AUC changed linearly with increasing doses between 0.5 and 7.5 mg/kg, which corresponds to 0.2 and 3 times the LD50 value in rats. Most of the drug was metabolized, and only 1%-2% and 10%-15% of the dose was eliminated unchanged by biliary and urinary excretion, respectively. The AUC of MMC at the LD50 is slightly less than that reported for the human MTD. Inoculation of MMC together with 5-fluorouracil and doxorubicin did not change the terminal half-life of MMC but decreased the total body clearance and the volume of distribution. The lack of significant influence of phenobarbital and 3-methylcholanthrene pretreatment on the terminal elimination half-life suggests that microsomal drug-metabolizing enzymes inducible by these compounds do not play a decisive role in the in vivo biotransformation of MMC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136940     DOI: 10.1007/bf00257305

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue hemogenates.

Authors:  H S SCHWARTZ; F S PHILIPS
Journal:  J Pharmacol Exp Ther       Date:  1961-09       Impact factor: 4.030

3.  Pharmacology of mitomycin C. I. Toxicity and pathologic effects.

Authors:  F S PHILIPS; H S SCHWARTZ; S S STERNBERG
Journal:  Cancer Res       Date:  1960-10       Impact factor: 12.701

Review 4.  Reductive drug metabolism.

Authors:  K E Mc Lane; J Fisher; K Ramakrishnan
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

5.  Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes.

Authors:  M Tomasz; R Lipman
Journal:  Biochemistry       Date:  1981-08-18       Impact factor: 3.162

6.  Relationship between clinical parameters and pharmacokinetics of mitomycin C.

Authors:  J Verweij; J den Hartigh; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

7.  Clinical pharmacokinetics of high-dose mitomycin C.

Authors:  R B Schilcher; J D Young; V Ratanatharathorn; C Karanes; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

Authors:  G A van Hazel; M Scott; J Rubin; C G Moertel; R T Eagan; M J O'Connell; J S Kovach
Journal:  Cancer Treat Rep       Date:  1983-09

9.  Metabolic activation of mitomycin C by liver microsomes and nuclei.

Authors:  K A Kennedy; S G Sligar; L Polomski; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  1982-06-01       Impact factor: 5.858

10.  Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase.

Authors:  S S Pan; P A Andrews; C J Glover; N R Bachur
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

View more
  6 in total

1.  The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

Authors:  J Verweij; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 2.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.

Authors:  Olaf Sørensen; Anders Andersen; Harald Olsen; Kristian Alexandr; Per Olaf Ekstrøm; Karl-Erik Giercksky; Kjersti Flatmark
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

4.  High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

Authors:  A Marinelli; D H Pons; J A Vreeken; S K Nagesser; P J Kuppen; U R Tjaden; C J van de Velde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo.

Authors:  L Chirrey; J Cummings; G W Halbert; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.

Authors:  A Marinelli; C J van de Velde; P J Kuppen; H C Franken; J H Souverijn; A M Eggermont
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.